top of page
Biosciences
Offspring
Insights & Updates
Four Reasons Antibody Programs Fail Before They Reach Patients
The most successful translational strategies increasingly focus on generating human-relevant evidence earlier, when development teams still have the opportunity to refine candidate selection, optimize trial design, and reduce uncertainty before major investments are made.
Featured
Search
Every Failed Program Looked Promising Once
Drug discovery has always involved making high-stakes decisions before all the answers are available. The challenge for R&D leadership is determining which uncertainties are acceptable, and which are systemic liabilities capable of derailing an entire program at the clinical threshold.
evadanielson55
Jun 154 min read
The One-Shot Gamble: Why Most IND-Enabling Programs Enter GLP-TCR With Too Little Data — and How to Change That
Offspring Biosciences | Tissue Insights™ | Preclinical Safety: Enhancing Drug Development There is a critical decision point in almost every therapeutic antibody program that deserves more strategic attention. This moment occurs just before the formal GLP Tissue Cross-Reactivity (TCR) study. This study is the FDA and EMA-mandated IHC screen of the drug candidate across a defined panel of normal human organ tissues. Without it, an IND cannot be filed. Most program teams treat
evadanielson55
May 124 min read
bottom of page